PMID- 7740450
OWN - NLM
STAT- MEDLINE
DCOM- 19950607
LR  - 20151119
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 72
IP  - 6
DP  - 1994 Dec
TI  - Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin 
      on coagulation activation at the site of plug formation in vivo.
PG  - 831-5
AB  - The clinical benefits of unfractionated heparin (UFH) and low molecular weight 
      heparin (LMWH) have been shown in many trials. However, the mode of action of 
      heparin has not been fully elucidated. Thus, we wanted to study the effects of 
      UFH and LMWH in vivo by measuring coagulation activation markers in blood 
      obtained directly from a vascular injury site. In a double-blind, randomized, 
      3-way, cross-over study 18 healthy volunteers were given UFH (150 U/kg s.c.) and 
      2 doses of LMWH [35 U/kg s.c. (low dose, ld), 75 U/kg s.c. (high dose, hd)]. 
      Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT) and 
      fibrinopeptide A (FPA) were measured in bleeding time blood and in venous blood 
      before and after drug application. In addition, the effects of UFH and LMWH on in 
      vitro coagulation tests were studied. Compared to base line, UFH and both ldLMWH 
      and hdLMWH caused significant reductions of F1+2, TAT and FPA in bleeding time 
      blood at 2 h. A marked effect of UFH and of hdLMWH was also seen at 5 h. The 
      inhibition of FPA generation was more pronounced after hdLMWH compared to ldLMWH. 
      In venous blood, UFH and LMWH caused reductions of F1+2, but not of TAT and FPA. 
      In vitro, UFH predominantly affected the anti-IIa assays (activated partial 
      thromboplastin time, thrombin time) and LMWH mainly the anti-Xa test system. 
      Using a technique that investigates the activated coagulation system in vivo, a 
      time- and dose dependent inhibitory effect of heparin on coagulation activation 
      was detectable.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Eichinger, S
AU  - Eichinger S
AD  - Department of Medicine I, Vienna University Hospital, Austria.
FAU - Wolz, M
AU  - Wolz M
FAU - Nieszpaur-Los, M
AU  - Nieszpaur-Los M
FAU - Schneider, B
AU  - Schneider B
FAU - Lechner, K
AU  - Lechner K
FAU - Eichler, H G
AU  - Eichler HG
FAU - Kyrle, P A
AU  - Kyrle PA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Biomarkers)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Peptide Fragments)
RN  - 0 (antithrombin III-protease complex)
RN  - 0 (prothrombin fragment 1.2)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9001-26-7 (Prothrombin)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antithrombin III/drug effects/metabolism
MH  - Biomarkers/blood
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Cross-Over Studies
MH  - Dalteparin/*pharmacology
MH  - Double-Blind Method
MH  - Factor Xa Inhibitors
MH  - Fibrinopeptide A/drug effects/metabolism
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Peptide Fragments/drug effects/metabolism
MH  - Peptide Hydrolases/drug effects/metabolism
MH  - Prothrombin/drug effects/metabolism
MH  - Thrombin Time
MH  - Veins
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1994 Dec;72(6):831-5.